FDA Grants New Indication for Imbruvica for Marginal Zone Lymphoma - Pharmacy Practice News

Medscape

FDA Grants New Indication for Imbruvica for Marginal Zone Lymphoma Pharmacy Practice News MZL is a slow-growing B-cell lymphoma occurring in lymphocytes at the edges of lymph nodes and various tissues, including the stomach, salivary glands, thyroid gland, eyes, lungs and spleen. ... “Patients with relapsed/refractory marginal zone lymphoma ... IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone ...Yahoo Finance all 12 news articles »

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jRROkL
via IFTTT